These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 10519405

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.
    Prevost GP, Pradines A, Brezak MC, Lonchampt MO, Viossat I, Ader I, Toulas C, Kasprzyk P, Gordon T, Favre G, Morgan B.
    Int J Cancer; 2001 Mar 01; 91(5):718-22. PubMed ID: 11267986
    [Abstract] [Full Text] [Related]

  • 23. CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase.
    McGuire TF, Qian Y, Blaskovich MA, Fossum RD, Sun J, Marlowe T, Corey SJ, Wathen SP, Vogt A, Hamilton AD.
    Biochem Biophys Res Commun; 1995 Sep 05; 214(1):295-303. PubMed ID: 7669049
    [Abstract] [Full Text] [Related]

  • 24. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
    Sebti SM, Hamilton AD.
    Expert Opin Investig Drugs; 2000 Dec 05; 9(12):2767-82. PubMed ID: 11093352
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells.
    Virtanen SS, Sandholm J, Yegutkin G, Kalervo Väänänen H, Härkönen PL.
    Cell Biol Int; 2010 Aug 05; 34(8):815-26. PubMed ID: 20446922
    [Abstract] [Full Text] [Related]

  • 26. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS.
    Leukemia; 2003 Feb 05; 17(2):451-7. PubMed ID: 12592346
    [Abstract] [Full Text] [Related]

  • 27. Pharmacological modulation of geranylgeranyltransferase and farnesyltransferase attenuates opioid withdrawal in vivo and in vitro.
    Rehni AK, Singh TG.
    Neuropharmacology; 2013 Aug 05; 71():19-26. PubMed ID: 23415632
    [Abstract] [Full Text] [Related]

  • 28. Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
    deSolms SJ, Ciccarone TM, MacTough SC, Shaw AW, Buser CA, Ellis-Hutchings M, Fernandes C, Hamilton KA, Huber HE, Kohl NE, Lobell RB, Robinson RG, Tsou NN, Walsh ES, Graham SL, Beese LS, Taylor JS.
    J Med Chem; 2003 Jul 03; 46(14):2973-84. PubMed ID: 12825937
    [Abstract] [Full Text] [Related]

  • 29. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K.
    Gan To Kagaku Ryoho; 1997 Sep 03; 24(11):1495-502. PubMed ID: 9309147
    [Abstract] [Full Text] [Related]

  • 30. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
    Mazzocca A, Giusti S, Hamilton AD, Sebti SM, Pantaleo P, Carloni V.
    Mol Pharmacol; 2003 Jan 03; 63(1):159-66. PubMed ID: 12488548
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
    Crespo NC, Delarue F, Ohkanda J, Carrico D, Hamilton AD, Sebti SM.
    Cell Death Differ; 2002 Jul 03; 9(7):702-9. PubMed ID: 12058275
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
    Kusama T, Mukai M, Tatsuta M, Matsumoto Y, Nakamura H, Inoue M.
    Clin Exp Metastasis; 2003 Jul 03; 20(6):561-7. PubMed ID: 14598891
    [Abstract] [Full Text] [Related]

  • 36. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
    Yonemoto M, Satoh T, Arakawa H, Suzuki-Takahashi I, Monden Y, Kodera T, Tanaka K, Aoyama T, Iwasawa Y, Kamei T, Nishimura S, Tomimoto K.
    Mol Pharmacol; 1998 Jul 03; 54(1):1-7. PubMed ID: 9658183
    [Abstract] [Full Text] [Related]

  • 37. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation.
    McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM.
    J Biol Chem; 1996 Nov 01; 271(44):27402-7. PubMed ID: 8910319
    [Abstract] [Full Text] [Related]

  • 38. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 39. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K, Nagasu T.
    Gan To Kagaku Ryoho; 1997 Jan 05; 24(2):145-55. PubMed ID: 9030225
    [Abstract] [Full Text] [Related]

  • 40. Theoretical studies on binding and specificity mechanisms of farnesyltransferase (FTase) and geranylgeranyltransferase type-I (GGTase-I) inhibitors by molecular modeling.
    Zhou S.
    Comb Chem High Throughput Screen; 2014 Jan 05; 17(6):509-19. PubMed ID: 24444014
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.